Floatz logo

Vinorelbine

Recurrent Marginal Zone Lymphoma

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Recurrent Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
Monomethyl Fumarate
Masonic Cancer Center, University of Minnesota
Phase 2BB

View all 50 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →